Centivax is a universal immunity company, deploying a proprietary computational immune-engineering platform to create vaccines and therapies that deliver universal protection against entire classes of diverse targets.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/10/25 | $45,000,000 | Series A |
Amplify Partners Base4 Capital BOLD Capital Partners Future Ventures  Kendall Capital Partners NFX | undisclosed |
